AUG 23, 2021 5:00 AM PDT

A Safe and Effective Combination Therapy for Advanced Cancer

WRITTEN BY: Katie Kokolus

Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have minimal therapeutic options. Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that block signals that would otherwise dampen the immune response. Nivolumab, an ICI used to treat many malignancies, including melanoma and kidney cancer, is commonly used in combination with other cancer therapies. 

The results of a multi-center phase 1 clinical trial recently published in Clinical Cancer Research demonstrated that combining nivolumab with entinostat, a histone deacetylase inhibitor drug, is a safe and effective strategy for treating patients with advanced cancer who have not responded to standard therapies. 

The study enrolled 33 patients with various solid tumors that had not responded to, on average, 3.5 previous therapeutic strategies. All patients received entinostat for two weeks. While continuing entinostat, patients received either nivolumab or nivolumab and a second ICI, ipilimumab.  

Adverse events associated with treatment were very mild and included symptoms like fatigue, nausea, and diarrhea. These minor side effects suggest that the combination therapy is safe and well-tolerated, an important consideration for physicians prescribing treatment for immunocompromised oncology patients.

Following treatment, the time to disease progression averaged 6.1 months. The average overall survival of patients in the study was 10.6 months. While 60% of the participants demonstrated clinical benefit, 44% achieved stable disease, indicating that the tumors stopped growing. One patient with triple-negative breast cancer had a complete response.  

The study team also evaluated the effects the treatment had on the immune response. Blood and tissue samples were collected three times throughout the study: before treatment, after two weeks of entinostat, and following ICI treatment. The ratio of CD8/FoxP3 increased following ICI treatment indicating a robust anti-tumor response. 

Specifically, these findings demonstrate that ICIs modulate two essential elements of anti-tumor immunity. First, cytotoxic CD8 T cells, the immune cells which directly kill cancer cells, are increased with ICI treatment.  Second, T regulatory cells, immune cells that regulate the immune system and suppress anti-tumor effects, are decreased with ICI treatment. 

This study highlights a unique therapeutic combination of a drug inhibitor and two ICIs. The findings encourage the need for additional trials testing combination therapies involving ICIs.  Further study could result in novel discoveries which will improve response rates in cancers that are currently untreatable.

Sources: Immunotherapies, immune checkpoint inhibitorsNivolumabClinical Cancer ResearchentinostatIpilimumab

 

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
DEC 19, 2021
Cancer
An Antibody to Clear the Way for Drug Delivery to Tumors
DEC 19, 2021
An Antibody to Clear the Way for Drug Delivery to Tumors
Tumors require blood vessels to obtain nutrients and growth factors needed for their expansion.  Many tumors effici ...
DEC 23, 2021
Cancer
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
DEC 23, 2021
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
It is estimated that nearly 84,000 people will be diagnosed with bladder cancer in the United States this year ...
DEC 30, 2021
Cancer
Integrative Oncology Prolongs Breast Cancer Survival
DEC 30, 2021
Integrative Oncology Prolongs Breast Cancer Survival
We often describe cancer according to where it originates, such as breast cancer, lung cancer, or pancreatic cancer.&nbs ...
JAN 24, 2022
Microbiology
Potential Anti-Cancer Bacterium Found in Antarctic Sea Squirt
JAN 24, 2022
Potential Anti-Cancer Bacterium Found in Antarctic Sea Squirt
Some of our best medicine has come from nature, and scientists are always on the lookout for natural products that can b ...
FEB 07, 2022
Cancer
Clinical Trial Demonstrates Beneficial Responses against a Rare form of Ovarian Cancer
FEB 07, 2022
Clinical Trial Demonstrates Beneficial Responses against a Rare form of Ovarian Cancer
Oncologists have identified five diverse subtypes of epithelial ovarian cancers: epithelial ovarian cancers as ...
FEB 21, 2022
Cell & Molecular Biology
A Stem Cell Transplant Cures HIV Patient
FEB 21, 2022
A Stem Cell Transplant Cures HIV Patient
Two people have been cured of HIV, and now, a US woman joins them. In this third case, stem cell transplants were being ...
Loading Comments...